Slide 1: Results Presentation – Q4 FY23
Results Presentation – Q4 FY23
Slide 2: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Hikal Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and
Slide 3: Executive Chairman's Message
Executive Chairman’s Message “For the financial year ’23, we achieved revenue of Rs 2,023 Crores, which is a growth of 4% as compared to last financial year. FY23 has been a challenging year where we witnessed significant headwinds in both our businesses. Despite the challenges we have recorded a se
Slide 4: Quarterly Financials Highlights
Quarterly Financials Highlights
Slide 5: Revenue – Q4 FY23 Rs. 545 Crore
Robust performance in both Pharmaceutical and Crop Protection businesses, with recovery in EBITDA margins Revenue – Q4 FY23 EBITDA – Q4 FY23 EBITDA Margin – Q4 FY23 Rs. 545 Crore Rs. 90 Crore 16.5% YoY QoQ YoY QoQ YoY QoQ +9% +1% +48% +21% +437 bps +271 bps PAT – Q4 FY23 EPS – Q4 FY23 Rs. 36 Crore R
Slide 6: Quarterly Performance Highlights
Quarterly Performance Highlights Revenue 540 545 Performance Highlights 502 • Revenue recorded an increase of 9% YoY and stood at Rs 545 Crore • Change in product mix • Increased demand of select products Q4FY22 Q3FY23 Q4FY23 • EBITDA stood at Rs 90 Crore, 48% increase on YoY basis EBITDA • Sequenti
Slide 7: Quarterly Performance Highlights – Pharmaceuticals
Quarterly Performance Highlights – Pharmaceuticals Revenue Pharmaceuticals - Performance Highlights 308 309 292 • Revenue stood flat at Rs 309 Crore vs same period last year • Sequentially improved QoQ sales • EBIT stood at Rs 36 Crore, 21% increase on YoY basis • Softening of key RM prices • Improv
Slide 8: Quarterly Performance Highlights – Crop Protection
Quarterly Performance Highlights – Crop Protection Revenue Crop Protection - Performance Highlights 248 236 • Revenue stood at Rs 236 Crore, 22% growth on YoY basis 194 • Improved product mix • Positive price movement of select products • EBIT stood at Rs 31 Crore, 167% growth on YoY basis • Softeni
Slide 9: Quarterly Financial Highlights
Quarterly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT 559 545 540 90 36 502 75 26 379 70 25 61 21 23 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 -9 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Rs. Crore © Hikal Limited
Slide 10: Quarterly Segmental Highlights
Quarterly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue 308 309 290 292 269 248 236 224 194 154 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Pharmaceuticals EBIT Crop Protection EBIT 35 36 31 30 27 26 11 12 10 -8 Q4FY22 Q1FY23 Q2FY23 Q3FY23 Q4FY23 Q4FY
Slide 11: Consolidated Profit & Loss – Q4
Consolidated Profit & Loss – Q4 Particulars (Rs. in Cr) Q4 FY23 Q4 FY22 Y-o-Y Q3 FY23 Q-o-Q Net Sales 545 502 9% 540 1% Expenditure 355 441 465 EBITDA 90 61 48% 75 21% Margin 16.5% 12.2% 13.8% Other Income 0 0 2 Depreciation 27 24 28 Finance Costs 13 8 13 PBT 49 29 68% 36 36% Tax 13 8 10 Net Profit
Slide 12: Annual Financials Highlights
Annual Financials Highlights
Slide 13: Financial Highlights - Annual
Financial Highlights - Annual Revenue – FY23 EBITDA – FY23 EBITDA Margin – FY23 Rs. 2,023 Crore Rs. 257 Crore 12.7% YoY YoY YoY +4% -25% -482 bps PAT – FY23 EPS – FY23 Rs. 78 Crore Rs 6.36 YoY YoY -51% -51% © Hikal Limited
Slide 14: Annual Performance Highlights
Annual Performance Highlights Revenue EBITDA PAT 1,943 2,023 341 161 257 78 FY22 FY23 FY22 FY23 FY22 FY23 Pharmaceuticals Division Crop Protection Division 1,130 1,115 908 813 Revenue Revenue FY22 FY23 FY22 FY23 151 115 103 65 EBIT EBIT Rs. Crore FY22 FY23 FY22 FY23 © Hikal Limited
Slide 15: Yearly Financial Highlights
Yearly Financial Highlights Consolidated Revenue Consolidated EBITDA Consolidated PAT 1,943 2,023 341 161 323 1,720 298 133 1,590 273 1,507 257 103 84 78 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Rs. Crore © Hikal Limited
Slide 16: Sales Break-Up
Sales Break-Up CDMO Own products Company Revenue Break-Up Pharmaceuticals Revenue Break-Up Crop Protection Revenue Break-Up 41% 45% 41% 52% 58% 56% 54% 63% 69% 77% 76% 74% 59% 55% 59% 48% 42% 44% 46% 37% 31% 23% 24% 26% FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 FY20 FY21 FY22 FY23 © Hikal Limited
Slide 17: Yearly Segmental Highlights
Yearly Segmental Highlights Pharmaceuticals Revenue Crop Protection Revenue 1,130 1,115 908 1,060 813 939 887 651 620 661 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Pharmaceuticals EBIT Crop Protection EBIT 170 112 115 151 103 103 129 100 128 65 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY
Slide 18: Consolidated Profit & Loss – Full Year
Consolidated Profit & Loss – Full Year Particulars (Rs. Crore) FY23 FY22 Y-o-Y Net Sales 2,023 1,943 4% Expenditure 1,766 1,602 EBITDA 257 341 -25% Margin 12.7% 17.5% Other Income 5 5 Depreciation 109 96 Finance Costs 48 31 Exceptional Item - - PBT 105 219 -52% Tax 27 58 Net Profit 78 161 -51% Margi
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet Assets (Rs. Crore) Mar-23 Mar-22 Equities & Liabilities (Rs. Crore) Mar-23 Mar-22 Total Non Current Assets 1,446 1,249 Shareholders Fund 1,134 1,068 Property, Plant and Equipment 885 815 Share Capital 25 25 Capital work in Progress 402 285 Other Equity 1,109 1,043 Right to
Slide 20: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Crore) Full Year ended 31-Mar-23 Full Year ended 31-Mar-22 Profit before tax 105 219 Adjustments 163 126 Operating Profit Before Working Capital Changes 268 345 Change in operating assets and liabilities 76 19 Cash generated from operations 344 364 I
Slide 21: Ratio Analysis
Ratio Analysis ROE ROCE 16.2% 16.1% 15.2% 15.0% 15.2% 12.5% 14.5% 10.7% 8.5% 7.1% FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 Net Debt / Equity Net Debt / EBITDA 0.83 0.71 2.62 0.61 0.59 0.61 2.11 2.13 1.78 1.81 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 © Hikal Limited
Slide 22: Annual Dividend Payout
Annual Dividend Payout Dividend Payout 24% 22% 18% 19% 17% 20% 19% 19% 12% 19% including DDT 13.02 EPS DPS 10.80 8.36 6.85 6.27 6.36 5.70 5.18 3.28 3.35 2.00 1.60 0.90 1.00 1.20 1.20 1.20 1.20 1.20 1.00 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 The above dividend is based on Face Value of Rs
Slide 23: Contact Us
Contact Us Company : Investor Relations Advisors : Hikal Limited Strategic Growth Advisors Pvt. Ltd. CIN: L24200MH1988PTC048028 CIN: U74140MH2010PTC204285 Mr. Kuldeep Jain Mr. Jigar Kavaiya / Ms. Ami Parekh +91-9920602034 / +91-8082466052 kuldeep_jain@hikal.com jigar.kavaiya@sgapl.net / ami.parekh@s
Slide 24: HIKAL
HIKAL